137 related articles for article (PubMed ID: 27748806)
1. NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Liu PY; Atmadibrata B; Mondal S; Tee AE; Liu T
Int J Oncol; 2016 Dec; 49(6):2464-2470. PubMed ID: 27748806
[TBL] [Abstract][Full Text] [Related]
2. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
[TBL] [Abstract][Full Text] [Related]
3. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
4. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
5. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
[TBL] [Abstract][Full Text] [Related]
6. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
7. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers.
Suenaga Y; Nakatani K; Nakagawara A
Jpn J Clin Oncol; 2020 Aug; 50(8):839-846. PubMed ID: 32577751
[TBL] [Abstract][Full Text] [Related]
8. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.
Shoji W; Suenaga Y; Kaneko Y; Islam SM; Alagu J; Yokoi S; Nio M; Nakagawara A
Biochem Biophys Res Commun; 2015 Jun; 461(3):501-6. PubMed ID: 25896758
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO.
Yang P; Chen T; Xu Z; Zhu H; Wang J; He Z
Oncotarget; 2016 Jul; 7(27):42183-42194. PubMed ID: 27259250
[TBL] [Abstract][Full Text] [Related]
10. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
11. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
[TBL] [Abstract][Full Text] [Related]
12. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
[TBL] [Abstract][Full Text] [Related]
13. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
14. Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression.
Li D; Chen Y; Mei H; Jiao W; Song H; Ye L; Fang E; Wang X; Yang F; Huang K; Zheng L; Tong Q
Oncogene; 2018 Aug; 37(35):4871-4886. PubMed ID: 29773901
[TBL] [Abstract][Full Text] [Related]
15. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.
Chen ST; Jeng YM; Chang CC; Chang HH; Huang MC; Juan HF; Hsu CH; Lee H; Liao YF; Lee YL; Hsu WM; Lai HS
Cancer Sci; 2011 Dec; 102(12):2191-8. PubMed ID: 21917080
[TBL] [Abstract][Full Text] [Related]
17. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
18. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
19. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY
Mol Oncol; 2021 Apr; 15(4):1162-1179. PubMed ID: 33497018
[TBL] [Abstract][Full Text] [Related]
20. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
